Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 3 8Phase 1/2 8Phase 1 4

Status

Completed 3Unknown 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Estramustine × Clear all
NCT00002721 2014-05-21

Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

University of New Mexico

Phase 1 Completed
18 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003633 2013-12-19

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 1 Unknown
12 enrolled
Genitourinary

Prostatic Neoplasms

NCT00005627 2013-07-18

Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

National Cancer Institute (NCI)

Phase 1 Completed
Genitourinary

Prostatic Neoplasms

NCT00005048 2012-11-09

Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NYU Langone Health

Phase 1 Completed
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡